Penbrook Management’s OptimizeRx OPRX Stock Holding History

Penbrook Management’s Portfolio OPRX Stock Details OPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-10,568	Closed	-$399K	–	109
2022 Q1	$399K	Buy	10,568 +3,493	+49%	+$155K	0.26%	81
2021 Q4	$439K	Sell	7,075 -91	-1%	-$6.9K	0.26%	78
2021 Q3	$613K	Hold	7,166	–	–	0.38%	71
2021 Q2	$444K	Buy	+7,166	New	+$365K	0.27%	82

Other funds holding OPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

GIPM

G2 Investment Partners Management New York $549M AUM 179.59% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Avenir Corporation Alexandria, Virginia $821M AUM 4.23% 1-Year Est. Return

Penbrook Management's OPRX Position: Q2 2022 in Review

Penbrook Management sold out of OptimizeRx (OPRX) in Q2 2022, closing a stake of 10,568 shares — an estimated $399K sold.

Penbrook Management first reported a position in OPRX in Q2 2021 and held it in 4 quarters. The position peaked at $613K in Q3 2021. 146 funds tracked by Wall St. Rank hold OPRX as of Q2 2022.

Penbrook Management reported no remaining OptimizeRx position as of Q2 2022 after selling out during the quarter.
Penbrook Management sold 10,568 OptimizeRx shares in Q2 2022, an estimated $399K.
Penbrook Management first reported a position in OptimizeRx in Q2 2021 and held it in 4 quarters.
Penbrook Management's OptimizeRx position peaked at $613K in Q3 2021.
146 funds tracked by Wall St. Rank held OptimizeRx as of Q2 2022.

Based on Penbrook Management's 13F filing for Q2 2022, filed 29 Jul 2022.